In a JAMA Viewpoint, CSPI authors argue a peptide-friendly advisory panel stacked with industry-tied members threatens drug approval integrity.
Recap by typeshit. Full story at Center for Science in the Public Interest.
The think tank argues regulated compounding beats 'research use only' sellers, noting an FDA panel voted to add six peptides despite staff advising against all seven.
Strive Specialties failed to revive its suit over GLP-1 competition. Novo still faces soft 2026 forecasts and an exploratory CagriSema analysis in women.
Reports say RFK Jr. backs an interim path for specialty compounding, while the FDA lists BPC-157 as a possible safety risk and doctors cite thin human evidence.
Belga reports the number of seized weight loss drugs in Belgium went up again, with officials concerned about an unofficial parallel market.
Bikman says midface volume drops about 7% for every 10 kg lost, and that bariatric surgery patients see the same change.
Nyah Phengsitthy reports Lilly is staking out a new battlefront around an unapproved obesity treatment. The full story has the details.
Loading…